Nuvation Bio (NUVB) Expected to Announce Earnings on Monday

Nuvation Bio (NYSE:NUVB) is expected to issue its Q4 2025 results after the market closes on Monday, March 2nd. Analysts expect the company to announce earnings of ($0.11) per share and revenue of $36.8220 million for the quarter. Interested persons can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Monday, March 2, 2026 at 4:30 PM ET.

Nuvation Bio Stock Up 2.0%

Shares of NYSE NUVB opened at $5.92 on Friday. The stock has a market capitalization of $2.03 billion, a PE ratio of -9.24 and a beta of 1.51. The company has a quick ratio of 8.39, a current ratio of 8.48 and a debt-to-equity ratio of 0.14. The firm has a fifty day moving average of $6.72 and a 200-day moving average of $5.46. Nuvation Bio has a 52-week low of $1.54 and a 52-week high of $9.75.

Insider Activity at Nuvation Bio

In other news, insider Dongfang Liu sold 150,000 shares of the firm’s stock in a transaction that occurred on Monday, December 1st. The shares were sold at an average price of $7.82, for a total transaction of $1,173,000.00. Following the completion of the sale, the insider owned 18,000 shares of the company’s stock, valued at approximately $140,760. This trade represents a 89.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 29.93% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in NUVB. Price T Rowe Associates Inc. MD boosted its stake in Nuvation Bio by 852.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company’s stock valued at $24,270,000 after purchasing an additional 2,424,109 shares during the period. Armistice Capital LLC boosted its position in shares of Nuvation Bio by 359.2% during the third quarter. Armistice Capital LLC now owns 2,296,000 shares of the company’s stock worth $8,495,000 after buying an additional 1,796,000 shares during the period. Millennium Management LLC grew its holdings in Nuvation Bio by 52.4% in the 1st quarter. Millennium Management LLC now owns 3,774,003 shares of the company’s stock worth $6,642,000 after buying an additional 1,298,131 shares in the last quarter. SymBiosis Capital Partners LLC acquired a new stake in Nuvation Bio in the 4th quarter valued at approximately $11,200,000. Finally, Two Sigma Investments LP raised its stake in Nuvation Bio by 95.7% during the 3rd quarter. Two Sigma Investments LP now owns 2,377,570 shares of the company’s stock valued at $8,797,000 after acquiring an additional 1,162,837 shares in the last quarter. 61.67% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

NUVB has been the subject of several research analyst reports. Citigroup restated a “market outperform” rating on shares of Nuvation Bio in a research note on Tuesday, November 4th. UBS Group started coverage on shares of Nuvation Bio in a research report on Wednesday, January 7th. They set a “neutral” rating and a $10.00 target price for the company. Wedbush restated an “outperform” rating and issued a $11.00 price target on shares of Nuvation Bio in a report on Tuesday, February 10th. Truist Financial set a $13.00 price objective on shares of Nuvation Bio in a research note on Tuesday, January 27th. Finally, Royal Bank Of Canada increased their price objective on shares of Nuvation Bio from $9.00 to $12.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.67.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.